Phio PharmaceuticalsPHIO -0.97%28 Buyback Yield % is -127.32 as of Jul. 11, 2026. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 742 Biotechnology companies, Phio Pharmaceuticals ranks worse than 92.32% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Phio Pharmaceuticals Buyback Yield % Related Terms
Phio Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Phio Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHIO vs PBM, KPRX, OSRH: Buyback Yield % Comparison
For the Biotechnology subindustry, Phio Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phio Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phio Pharmaceuticals (PHIO) has a Buyback Yield % of -127.32 as of Jul. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Phio Pharmaceuticals and its competitors. According to the industry distribution chart, Phio Pharmaceuticals ranks #685 out of 742 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Phio Pharmaceuticals' Buyback Yield % too high?
Phio Pharmaceuticals' current Buyback Yield % is -127.32. Based on the distribution chart, Phio Pharmaceuticals ranks #685 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' Buyback Yield % compare to PBM and KPRX?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #685 out of 742 companies for Buyback Yield %. This places Phio Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Phio Pharmaceuticals and its competitors. Phio Pharmaceuticals's current Buyback Yield % is -127.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current Buyback Yield % of -127.32. The current Buyback Yield % is -127.32. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current Buyback Yield % is -127.32 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score
Get the complete analysis for PHIO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHIO has been successfully added to your 
